Decadron
NDC Package 58463-010-08
Package Information
Decadron is endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance).Congenital adrenal hyperplasiaNonsuppurative thyroiditisHypercalcemia associated with cancer Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:Psoriatic arthritisRheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)Ankylosing spondylitisAcute and subacute bursitisAcute nonspecific tenosynovitisAcute gouty arthritisPost-traumatic osteoarthritisSynovitis of osteoarthritisEpicondylitis Collagen Diseases: During an exacerbation or as maintenance therapy in selected cases of:Systemic lupus erythematosusAcute rheumatic carditis Dermatologic Diseases:PemphigusBullous dermatitis herpetiformisSevere erythema multiforme (Stevens-Johnson syndrome)Exfoliative dermatitisMycosis fungoidesSevere psoriasisSevere seborrheic dermatitis Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment:Seasonal or perennial allergic rhinitisBronchial asthmaContact dermatitisAtopic dermatitisSerum sicknessDrug hypersensitivity reactions Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as:Allergic conjunctivitisKeratitisAllergic corneal marginal ulcersHerpes zoster ophthalmicusIritis and iridocyclitisChorioretinitisAnterior segment inflammationDiffuse posterior uveitis and choroiditisOptic neuritisSympathetic ophthalmia Respiratory Diseases:Symptomatic sarcoidosisLoeffler's syndrome not manageable by other meansBerylliosisFulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapyAspiration pneumonitis Hematologic Disorders:Idiopathic thrombocytopenic purpura in adultsSecondary thrombocytopenia in adultsAcquired (autoimmune) hemolytic anemiaErythroblastopenia (RBC anemia)Congenital (erythroid) hypoplastic anemia Neoplastic Diseases: For palliative management of:Leukemia and lymphomas in adultsAcute leukemia of childhood Edematous States: To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases: To tide the patient over a critical period of the disease in:Ulcerative colitisRegional enteritis Miscellaneous:Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapyTrichinosis with neurologic or myocardial involvement Diagnostic testing of adrenocortical hyperfunction. Marketed by Pragma Pharmaceuticals, Llc, this product is identified by NDC 58463-010 and is authorized under FDA application ANDA090891.
Identification & Billing
- RxCUI: 309686 - dexAMETHasone 0.5 MG in 5 mL Oral Solution
- RxCUI: 309686 - dexamethasone 0.1 MG/ML Oral Solution
- RxCUI: 309686 - dexamethasone 0.5 MG per 5 ML Oral Solution
- RxCUI: 309686 - dexamethasone 1 MG per 10 ML Oral Solution
- RxCUI: 755976 - Decadron 0.5 MG in 5 mL Oral Solution
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 58463 - Pragma Pharmaceuticals, Llc
- 58463-010 - Decadron
- 58463-010-08 - 237 mL in 1 BOTTLE
- 58463-010 - Decadron
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 58463-010-08 identifies a specific commercial package of 237 ml in 1 bottle of Decadron, labeled by Pragma Pharmaceuticals, Llc. This product is billed per "ML" milliliter and contains an estimated amount of 237 billable units per package. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Pragma Pharmaceuticals, Llc on March 15, 2018. The current certification is valid through December 31, 2019.
How is this Pragma Pharmaceuticals, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 58463001008. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 237 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.